Literature DB >> 27873275

Terminal Repeat Analysis of EBV Genomes.

Ferenc Bánáti1, Anita Koroknai2, Kálmán Szenthe3.   

Abstract

Epstein-Barr virus (EBV) was the first human virus associated directly with human malignancies. During EBV infection of various host cells the double-stranded linear EBV DNA carried by the virions undergoes circularization. Since there are variable numbers of terminal repetitions (TRs) at the ends of the linear EBV genome, the resulting circular episomes enclose a variable number of TRs. Thus, in cells carrying viral episomes, the sizes of the terminal restriction enzyme fragments of EBV is affected by the number of TRs (Raab-Traub and Flynn Cell 47:883-889, 1986). Southern blot analysis revealed that in monoclonal proliferations, arising from a single cell, there was only a single band representing the joined EBV termini, whereas multiple terminal restriction enzyme fragments that differ in size were characteristic for oligoclonal or polyclonal proliferations. Using suitable probes, one can distinguish the episomal form from the linear EBV genomes that are formed during lytic EBV replication or during integration into the host genome. TR analysis is a useful tool for the determination of EBV clonality in different clinical samples and in cell lines carrying EBV genomes. A single terminal restriction enzyme fragment may indicate EBV infection at an early phase of clonal cell proliferation, whereas polyclonal EBV genomes may derive from multiple infections of proliferating cells.

Entities:  

Keywords:  Clonality; EBV infection; Terminal repeat

Mesh:

Year:  2017        PMID: 27873275     DOI: 10.1007/978-1-4939-6655-4_12

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

Review 1.  Potential Role of Epstein-Barr Virus in Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma: A Scoping Review.

Authors:  Rifat Rahman; Divya Gopinath; Waranun Buajeeb; Sopee Poomsawat; Newell W Johnson
Journal:  Viruses       Date:  2022-04-13       Impact factor: 5.818

Review 2.  Progress in Prophylactic and Therapeutic EBV Vaccine Development Based on Molecular Characteristics of EBV Target Antigens.

Authors:  Marija Rozman; Petra Korać; Karlo Jambrosic; Snjezana Židovec Lepej
Journal:  Pathogens       Date:  2022-07-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.